Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...
Press releases
-
ICON hosts investor day and updates full year 2024 financial guidance
ICON plc will host its 2024 Investor Day today in New York City.
-
ICON plc to hold Investor Day meeting on May 30, 2024
This press release contains forward-looking statements, including statements about our financial guidance.
-
ICON releases its ICON Cares 2023 Report
This outlines how the company is delivering on its ESG, diversity, inclusion and belonging, and CSR goals, as delivered through its ICON Cares program.
-
ICON announces pricing of USD 2 billion notes
Consisting of $750,000,000 5.809% Senior Secured Notes due 2027, $750,000,000 5.849% Senior Secured Notes due 2029 and $500,000,000 6.000% Senior Secured Notes due 2034 (collectively, the “Notes”).
-
ICON reports first quarter 2024 results
Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis.
-
ICON announces CFO transition
ICON today announced that Chief Financial Officer, Brendan Brennan, will leave his role at ICON in quarter four this year for a new opportunity outside of the CRO industry.
-
ICON plc schedules first quarter 2024 earnings conference call
Will hold a conference call and webcast to discuss its financial results and performance on 25 April, 2024.
-
ICON reports fourth quarter and full year 2023 results
Full year net business wins of $9,946 million; a net book to bill of 1.22.
-
New ICON survey highlights importance of combination therapies in future obesity treatment
ICON announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area.
-
ICON issues financial guidance for full year 2024
ICON plc today announced its financial guidance for the year ending December 31, 2024.
